Effect of solvents quality on determination of particle size and polydispersity of nanoparticles
Source abstract
Abstract
Nanotechnology is of great interest to researchers and industrialists and nanocolloidal carrier systems for drug delivery have been studied in great detail, but while much research has been carried out on the preparation of nanoparticles using a variety of techniques employing various solvents, no attention has been given to the quality of solvents used in the process of nanoparticles characterization. The present investigation aimed to study the effect of solvents quality on the chitosan nanoparticles characterization for average particle size (Z) and polydispersity index (P.I.). Particle size distribution study showed that the number of particles contributed by solvents significantly affects both the Z and P.I. of the nanoparticulate suspensions leading to ambiguous results. While the Z decreases upon dilution with organic solvents, the phosphate buffer and water causes a net increase in Z because of the introduction of larger extraneous nanoparticles. The P.I. was found to increase with dilution because of the differences in the size of the polymeric nanoparticles and the nanoparticles introduced by the solvent upon dilution. The study thus recommends use of the highest quality of solvents in nanoparticles manufacturing and characterization process to avoid the generation of erroneous results.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Surfactants and Colloidal Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (19)
Show source-provided references
1. Dowling AP · Nanotoday · 2004 · 1 · 30
2. Pitkethly MJ · Nanotoday · 2004 · 1 · 20
3. Holister P · 2002 · 1
4. 10.1023/A:101209800509810.1023/A:1012098005098 ↗
5. 10.1023/A:101192160896410.1023/A:1011921608964 ↗
6. 10.1023/A:101197362580310.1023/A:1011973625803 ↗
7. 10.1016/j.biomaterials.2004.10.02510.1016/j.biomaterials.2004.10.025 ↗
8. 10.1016/S0168-3659(02)00212-210.1016/S0168-3659(02)00212-2 ↗
9. 10.1208/pt05045310.1208/pt050453 ↗
10. 10.1016/S0928-0987(03)00019-810.1016/S0928-0987(03)00019-8 ↗
11. 10.1016/S0168-3659(02)00239-010.1016/S0168-3659(02)00239-0 ↗
12. 10.1016/j.ijpharm.2004.11.02710.1016/j.ijpharm.2004.11.027 ↗
13. 10.1016/S0939-6411(96)00037-910.1016/S0939-6411(96)00037-9 ↗
14. 10.1081/DDC-12002131810.1081/DDC-120021318 ↗
15. 10.1080/02652040041765810.1080/026520400417658 ↗
16. Mattison KW · American Biotechnology · 2004 · 12 · 1
17. 10.1016/S0928-0987(03)00178-710.1016/S0928-0987(03)00178-7 ↗
18. 10.1002/jps.260082090910.1002/jps.2600820909 ↗
19. 10.1002/jbm.102910.1002/jbm.1029 ↗